# Precision IFX: Using a Dashboard to Individualize Infliximab Dosage

> **NCT02624037** · NA · COMPLETED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 189 (actual)

## Conditions studied

- Inflammatory Bowel Disease

## Interventions

- **OTHER:** Individualized Dosage Precision IFX Dashboard

## Key facts

- **NCT ID:** NCT02624037
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2020-10-21
- **Final completion:** 2020-10-21
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2021-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02624037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02624037, "Precision IFX: Using a Dashboard to Individualize Infliximab Dosage". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02624037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*